Low-Dose Valganciclovir for CMV Prophylaxis after Lung Transplantation

Table 2

Characteristics of the people who developed CMV disease.

Patient’s age at transplant	CMV serostatus D/R	Time after transplant to; develop CMV disease	Time after stopping valganciclovir to develop CMV disease
52 years	D+/R−	32 months	24 months
66 years	D+/R+	8 months	2 months
60 years	D−/R−	23 months	17 months
57 years	D+/R−	15 months	9 months
70 years	D+/R+	8 months	5 months